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Wei Zhao, Soumya Jaganathan, and James Turkson1
From the Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, Florida 32827
Given the role of constitutively active Signal Transducer and
Activator of Transcription (Stat) 3 in human tumors, Stat3
inhibitors would be useful as novel therapeutics and as tools for
probing Stat3-mediated tumor processes. We herein report that
a 28-mer peptide, SPI, derived from the Stat3 SH2 domain, replicates Stat3 biochemical properties. Studies show SPI and Stat3
(or Stat3 SH2 domain) bind with similar affinities to known
Stat3-binding phosphotyrosine (pY) peptide motifs, including
those of the epidermal growth factor receptor (EGFR) and the
high-affinity, IL-6R/gp130-derived pY-peptide, GpYLPQTVNH2. Consequently, SPI functions as a potent and selective
inhibitor of Stat3 SH2 domain:pTyr interactions and disrupts
the binding of Stat3 to the IL-6R/gp130 peptide, GpYLPQTVNH2. Fluorescence imaging and immunofluorescence staining/
laser-scanning confocal microscopy show SPI is cell membranepermeable, associates with the cytoplasmic tail of EGFR in
NIH3T3/hEGFR, and is present in the cytoplasm, but strongly
localized at the plasma membrane and in the nucleus in malignant cells harboring persistently active Stat3. Moreover, SPI
specifically blocks constitutive Stat3 phosphorylation, DNA
binding activity, and transcriptional function in malignant cells,
with little or no effect on the induction of Stat1, Stat5, and Erk1/
2MAPK pathways, or on general pTyr profile at the concentrations that inhibit Stat3 activity. Significantly, treatment with SPI
of human breast, pancreatic, prostate, and non-small cell lung
cancer cells harboring constitutively active Stat3 induced extensive morphology changes, associated with viability loss and apoptosis. Our study identifies SPI as a novel molecular probe for
interrogating Stat3 signaling and that functions as a selective
inhibitor of Stat3 activation with antitumor cell effects.

The binding of cytokines or growth factors to cognate receptors initiates a cascade of molecular events that culminate in the
activation of the Signal Transducer and Activator of Transcription (STAT) family of proteins (1, 2). Among these is the
recruitment of STATs, via the SH2 domain, to the receptor
phosphotyrosine (pTyr)2 peptide motifs, which brings them
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into close proximity for phosphorylation on a key tyrosyl residue by growth factor receptor tyrosine kinases, Janus kinases
(Jaks), and the Src family kinases. Consequently, dimerization
between two STAT monomers is promoted through a reciprocal pTyr-SH2 domain interaction, and the active STAT dimers
in the nucleus bind to specific DNA-response elements in the
promoters of target genes and regulate gene expression. In
response to growth factors and cytokines, normal STAT signaling promotes cell growth and differentiation, development,
inflammation, and immune responses.
The STAT proteins are modular in structure and contain
N-terminal domain, coiled-coil domain, DNA-binding domain,
SH2 domain, and a transcriptional activation domain, with
each domain engaging in important molecular events for promoting STAT functions. In particular, the SH2 domain mediates crucial interactions with specific pTyr peptide motifs,
including promoting the association with receptors and holding up two activated STAT monomers together in a reciprocal
SH2 domain:pTyr interactions in STAT:STAT dimerization.
Among the STAT family members, Stat3 and Stat5 have been
strongly implicated in malignant transformation and tumorigenesis (3–7) and have become valid targets for anticancer drug
design. In general, given the role of the SH2 domain as an
important motif in signal transduction, in relation to engaging in interactions with pTyr peptide modules (8), there are
considerable efforts to design probes that disrupt these
interactions for potential application as drugs (9 –12). For
Stat3, pTyr peptide mimetics have been shown to suppress
its functions. Thus, the Stat3 SH2 domain:pTyr peptide
interaction has become an attractive target in many drug
design strategies intended to identify small molecule inhibitors as new therapeutics for cancers in which aberrant Stat3
activity is implicated (4, 5, 13–22).
Whereas the focus of the existing Stat3 drug discovery efforts
have been on disrupting the Stat3 SH2 domain:pTyr peptide
interactions for a good reason, the approaches have largely been
directed at SH2 domain antagonists, which are pTyr peptide
mimics that compete for the binding to the Stat3 SH2 domain
(4, 5, 22). One of the major limitations of this approach has been
finding a membrane-permeable, optimum pTyr substitute that
retains the high binding affinities of the native pTyr peptide
motifs, against which these antagonists will be competing for
the binding to the Stat3 SH2 domain. To eliminate this issue, we
have taken the converse approach of identifying a suitable Stat3
SH2 domain-mimic. Key structural information from the comtogen-activated protein kinase; GOLD, genetic optimization for ligand
docking; SPR, surface plasmon resonance; FP, fluorescence polarization.
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putational modeling of the native pTyr peptide, PpYLKTK
bound to the Stat3 SH2 domain, per the crystal structure of
Stat3␤ (23) facilitated the design of a 28-mer peptide, SPI from
the Stat3 SH2 domain. Studies presented herein show that SPI
retains the binding characteristics of the SH2 domain. In vitro
biochemical and biophysical studies indicate SPI, like Stat3
binds to cognate pTyr-peptide motifs with a similar affinity.
Accordingly, SPI blocks the binding of Stat3 (or Stat3 SH2
domain) to cognate pTyr peptide motifs, and hence functions
as a selective inhibitor of constitutive Stat3 activation in human
breast, prostate, pancreatic, and non-small cell lung cancer
cells, with antitumor cell effects.

EXPERIMENTAL PROCEDURES
Cells and Reagents—Normal mouse fibroblasts (NIH3T3)
and counterparts transformed by v-Src (NIH3T3/v-Src) or
overexpressing the human epidermal growth factor (EGF)
receptor (NIH3T3/hEGFR), and the human breast (MDA-MB231, MDA-MB-435, and MCF-7), pancreatic (Colo-357), prostate (DU145 and LNCaP), non-small cell lung (A549) cancer,
and TE-71 mouse thymus epithelial stromal cells have all been
previously reported (14, 24 –28). The Stat3-dependent reporter, pLucTKS3 and the Stat3-independent reporter, pLucSRE,
and the v-Src transformed mouse fibroblasts that stably express
pLucTKS3 (NIH3T3/v-Src/pLucTKS3) or pLucSRE (NIH3T3/
v-Src/pLucSRE), and the Stat3-independent ␤-casein luciferase
reporter (␤-Casein-Luc) driven by the Stat5-responsive ␤-casein promoter have been previously reported (13, 14, 16, 29, 30).
Cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% heat-inactivated fetal bovine serum.
Peptide Synthesis—The Stat3 SH2 domain peptide sequence,
FISKERERAILSTKPPGTFLLRFSESSK was purchased from
Peptide 2.0 (Fairfax, VA) at ⬎95% purity.
Cloning and Protein Expression—The molecular cloning,
expression, and the purification of His-tagged Stat3 and Histagged Stat3 SH2 domain were carried out as we have previously reported (27). Clones were sequenced to verify the correct
sequences and orientation. His-tagged recombinant proteins
were expressed in BL21(DE3) cells and purified on Ni-ion
Sepharose column.
Transient Transfection of Cells and Treatment with SPI—
12–24 h following seeding, mouse fibroblasts overexpressing
hEGFR (NIH3T3/hEGFR) in 6-well plates were transiently cotransfected with 4 g of ␤-casein Luc and 500 ng of ␤-galactosidase (for normalizing) for 8 h using Lipofectamine plus
(Invitrogen, Carlsbad, CA) and following the manufacturer’s
protocol. Twelve hours after transfection, cells were treated or
untreated with increasing concentration of SPI (0 – 60 M) for
12 h prior to stimulation with rhEGF (10 ng/l) and allowed to
culture for additional 12 h, after which cells were harvested and
cytosolic extracts prepared for luciferase assay, as previously
performed (16, 29, 30).
Cytosolic Extracts and Luciferase Assay—Cytosolic extract
preparation from mammalian cells for luciferase assay has been
described previously (29, 30). Luciferase assays were carried out
according to the supplier’s (Promega, Madison, WI) manual
and measured with a luminometer (Lumat LB 9507, EG&G
Berthold, Germany).
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Nuclear Extract Preparation and Electrophoretic Mobility
Shift Assay—Nuclear extract preparation and electrophoretic
mobility shift assay (EMSA) were carried out as previously
described (25, 30). The 32P-labeled oligonucleotide probes used
were hSIE (high affinity sis-inducible element from the c-fos
gene, m67 variant, 5⬘-AGCTTCATTTCCCGTAAATCCCTA)
that binds Stat1 and Stat3 (31) and MGFe (mammary gland
factor element from the bovine ␤-casein gene promoter,
5⬘-AGATTTCTAGGAATTCAA) for Stat1 and Stat5 binding
(32, 33). Where appropriate, cells in culture were pretreated
with SPI for 12 h, prior to treatment with sodium orthovanadate for 12 h or stimulation with EGF (10 ng/l) for 12 min and
then harvested for nuclear extract preparation.
SDS-PAGE/Western Blotting Analysis—SDS/PAGE and
Western blotting analysis were performed as previously described (30, 34). Primary antibodies used were anti-Stat3,
pY705Stat3, pErk1/2, and Erk1/2 (Cell Signaling).
Cell Viability, Proliferation, and Annexin V/Flow Cytometry
Studies—Cells in culture in 6-well or 96-well plates were
treated with or without 50 M SPI for 24 – 48 h and subjected to
CyQuant cell proliferation assay (Invitrogen Corp), or harvested, and the viable cells counted by trypan blue exclusion
with phase contrast microscopy, or cells were processed for
Annexin V and 7-AAD binding (BD Biosciences, San Jose, CA)
with flow cytometry for apoptosis.
Fluorescence Imaging and Immunofluorescence with Laserscanning Confocal Microscopy—Studies were performed as
previously reported (35). Briefly, human breast cancer, MDAMB-231, or NIH3T3/hEGFR cells were grown in multi-cell
plates on slides or not, and treated with or without 5-carboxyfluorescein-labeled SPI or unlabeled SPI (30 M) for 3 h. Cells
were washed with 1⫻ phosphate-buffered saline (PBS), fixed
with ice-cold methanol, and visualized using Zeiss Axiovert 200
microscope (Zeiss, Germany) for fluorescent images, or for
confocal microscopy, cells were washed three times with 1⫻
PBS, fixed with ice-cold methanol for 15 min, washed three
times in PBS, permeabilized with 0.2% Triton X-100 for 10 min,
and further washed 3–4 times with PBS. Specimens were then
blocked in 1% bovine serum albumin (BSA) for 1 h and incubated
with anti-EGFR antibody (Santa Cruz Biotechnology) or rabbit
polyclonal anti-Stat3 antibody (Cell Signaling) at 1:50 dilution at
4 °C overnight. Subsequently, cells were rinsed 4 –5 times in PBS,
incubated for 1 h at room temperature in the dark with AlexaFluor
546 rat secondary antibody for anti-EGFR antibody detection
(Invitrogen) or AlexaFluor546 (donkey anti-rabbit) secondary
antibody for anti-Stat3 antibody detection. Specimens were then
washed five times with PBS, covered with cover slides with
VECTASHIELD mounting medium containing DAPI, and examined immediately under a Leica TCS SP5 confocal microscope
(Germany) at appropriate wavelengths. Images were captured and
processed using the Leica TCS SP 5 software.
Fluorescence Polarization Assay—Fluorescence Polarization
(FP) Assay was conducted as previously reported (20, 27)
using the labeled phosphopeptide, 5-carboxyfluoresceinGpYLPQTV-NH2 (where pY represents phospho-Tyr) as
probe and Stat3 or SPI. For saturation curves, a fixed concentration of the fluorescently labeled peptide probe (10 nM)
was incubated with increasing concentration of Stat3 (0 – 0.8
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M) or SPI (0 – 400 M) for 30 min at room temperature in the
buffer, 50 mM NaCl, 10 mM HEPES, 1 mM EDTA, 0.1% Nonidet
P-40, and the fluorescent polarization measurements were
determined using the POLARstar Omega (BMG LABTECH,
Durham, NC), with the set gain adjustment at 35 mP. For evaluating the effect of SPI as an inhibitor on Stat3 binding to pY
peptide, a fixed concentration of Stat3 protein (0.8 M) was
preincubated with serial concentrations of SPI (0 –150 M), or
in the case of the effect of the Stat3 inhibitor, S3I-201 on the
binding of Stat3 or SPI to probe, a fixed amount of Stat3 (200
nM) or SPI (150 M) was preincubated with increasing concentration of S3I-201 at 30 °C for 60 min in the indicated assay
buffer conditions, prior to the addition of the labeled probe.
Probe was then added at a final concentration of 10 nM and
incubated for 30 min at room temperature following which the
FP measurements were taken using the POLARstar Omega,
with the set gain adjustment at 35 mP.
Surface Plasmon Resonance Analysis—SensiQ and its analysis software Qdat (ICX Technologies, Oklahoma City, OK)
were used to analyze the interaction between known Stat3binding pTyr peptide motifs (analyte) and Stat3 or the Stat3
SH2 domain (target) and to determine the binding affinity, as
previously reported (27). Purified Stat3 (50 g), Stat3 SH2
domain (30 g), or SPI (25 g) was immobilized on a Carboxyl
Sensor Chip (for SPI) or a HisCap Sensor Chip (for Stat3 and
the Stat3 SH2 domain) by injecting the peptide or protein onto
the chip. Various concentrations of pTyr peptides (analyte) in
running buffer (1⫻ PBS, 0.5% DMSO) were passed over the
sensor chip to produce response signals. The response signals
were referenced by subtracting the response generated by passing across the unoccupied chip surface the running buffer with
the analytes. The association and dissociation rate constants
were calculated using the Qdat software. The ratio of the association and dissociation rate constants was determined as the
affinity (KD).
Statistical Analysis—Statistical analysis was performed on
mean values using Prism GraphPad Software, Inc. (La Jolla,
CA). The significance of differences between groups was determined by the paired t test at p ⬍ 0.05 (*), ⬍ 0.01 (**), and ⬍ 0.001
(***).

RESULTS
Computer-aided Design of SPI as a Molecular Probe and
Stat3 Inhibitor—Close structural analysis of the lowest Genetic
Optimization for Ligand Docking (GOLD) (36) conformation
of the native pTyr peptide, PpYLKTK bound within the Stat3
SH2 domain (16), per the x-ray crystal structure of Stat3␤
homodimer (23), showed significant complementary interactions at the protein surface, by which a minimum SH2 domain
peptide sequence was derived that retains interactions with the
pTyr peptide. The lowest energy GOLD docking studies consistently showed the pTyr peptide making hydrogen bonds and
electrostatic interactions with the key residues, Lys-591, Ser611, Ser-613, and Arg-609 of the SH2 domain. The SH2 domain
peptide, SPI, is composed of amino acid residues 588 – 615,
which incorporate the aforementioned key residues (Fig. 1C).
Fig. 1A shows the spatial presentation of the 28-mer peptide
(28-mer, green overlay) within the context of the three-dimenNOVEMBER 12, 2010 • VOLUME 285 • NUMBER 46

FIGURE 1. Computer modeling of Stat3 or the Stat3 SH2 domain peptide
(SPI) and SPI amino acid sequence. A, the spatial presentation of the 28-mer
peptide (28-mer, green overlay) within the context of the three-dimensional
structure of Stat3 (red), per the x-ray crystal structure of DNA-bound Stat3␤.
B, structure of SPI, as modeled using ModWeb (University of California, San Francisco (UCSF)) and viewed by UCSF Chimera software. Model Score, 0.87; and C,
amino acid sequence for residues 588 – 615 of the Stat3 SH2 domain.

TABLE 1
Sequence homology between SPI and SH2 motifs of select human
proteins
Alignment and homology were determined using NCBI Blast.
Protein

Gene ID

Identity

Stat3
Stat1
Stat4
Stat2
Stat6
Stat5A
Stat5B
Fyn
Fgr
Src
TNS3
SH2D2A

6774
6772
6775
6773
6778
6776
6777
2534
2268
6714
64759
9047

100
78
73
57
57
53
53
53
50
50
48
44

%

sional structure of Stat3 (red), per the x-ray crystal structure of
Stat3␤ (23), and Fig. 1B shows the three-dimensional structure
of the 28-mer as developed per comparative modeling method
using ModWeb (University of California, San Francisco
(UCSF)) (37), with a score of 0.87, and viewed by Chimera software (UCSF) (38) (because of ModWeb software requirements,
of a minimum of 30 amino acids, three Gly residues were added
to the N terminus of the 28-mer during the modeling, but were
eliminated at the time of viewing with Chimera software).
Sequence alignment analysis of SPI with SH2 motifs from other
proteins reveals high homologies, 78% and 73%, respectively, to
the Stat1 and Stat4 SH2 domains, and 40 –57% homologies to
the other proteins evaluated, including Stat2, Stat5, Stat6, Src,
Fyn, Fgr, TNS3 (Tensin-3 protein), and SH2D2A (SH2 domain
protein 2A) (Table 1). Molecular modeling raises the potential
that SPI retains significant three-dimensional structural characteristics as in the full-length Stat3 protein. Studies were conducted for the characterization of the biochemical and biophysical properties of SPI relative to Stat3, and to determine the
potential to inhibit Stat3 activation and functions.
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In Vitro Evidence That SPI Interacts with Cognate pTyr Peptide Motifs and Disrupts the Binding of Stat3 or the Stat3 SH2
Domain—We presume that SPI would bind to pTyr peptide
motifs that are known to bind to Stat3. To provide definitive
evidence of direct binding of SPI to known Stat3-binding pTyr
peptide motifs and to compare with the binding of Stat3 or the
Stat3 SH2 domain, biophysical studies were performed. Purified, His-tagged Stat3 protein (50 g) or His-tagged Stat3 SH2
domain (30 g), or SPI (25 g) was immobilized (target) on a
Ni-NTA or carboxyl sensor chip surface for SPR analysis of the
binding to pTyr peptides (analyte). Association and dissociation measurements were taken and the affinities were determined using Qdat software. We considered the known Stat3binding pTyr peptide motifs, PpYLKTK (pY705Stat3 involved
in Stat3:Stat3 and Stat1:Stat3 dimerization events), GpYIKTE
(pY701Stat1 involved in Stat1:Stat1 and Stat1:Stat3 dimerization events), PEpYINQS and PVpYHNQP (pY1068EGFR and
pY1086EGFR, respectively), and GpYLPQTV (IL-6R/gp130),
and the probable binding motif, GpYVKPQ (pY694Stat5) (pTyr
peptide sequences were derived from the NCBI protein data
base), and the previously reported Stat3 dimerization inhibitor
and the SH2 domain antagonist, S3I-201 (16).
Overall, the interactions with the aforementioned pTyr peptides (analytes) were comparable for the three targets, SPI (Fig.
2A), Stat3 SH2 domain (Fig. 2B), and Stat3 (Fig. 2C). Specifically, the interactions with the gp130-derived peptide,
GpYLPQTV, were of the highest affinity, with KD values of 50.0,
30.0, and 20.0 nM, respectively, for SPI, Stat3 SH2 domain
and Stat3 (Fig. 2, GpYLPQTV). Relative to these affinities,
the interactions with the Stat3-derived pY705 peptide,
PpYLKTK were 13–100-fold weaker, with KD values of 0.6,
1.6, and 0.9 M, for SPI, Stat3 SH2 domain, and Stat3, respectively (Fig. 2, PpYLKTK), as were the interactions with the
pY1068 of EGFR, PEpYINQS, with KD values of 0.4, 0.4, and
0.6 M, respectively, for SPI, Stat3 SH2 domain, and Stat3 (Fig.
2, PEpYINQS). Even much weaker were the interactions of the
three targets with the pY1086 peptide of EGFR, PVpYHNQP,
with KD values of 4.2, 2.6, and 3.8 M, respectively, for SPI, Stat3
SH2 domain, and Stat3, suggesting with respect to the two
known Stat3-binding EGFR pTyr motifs, pY1068EGFR
(PEpYINQS) and pY1086EGFR (PVpYHNQP), Stat3 and SPI
display differential binding. A surprising finding is the relatively
weaker binding to the Stat1 pY701 peptide, GpYIKTE, with KD
values of 7.6, 6.6, and 4.4 M, for SPI, Stat3 SH2 domain, and
Stat3, respectively, which compared with the binding to Stat3
pY705 peptide (PpYLKTK) represent 3–13-fold difference in
affinity, despite there being 78% sequence homology between
the Stat3 and Stat1 SH2 domains (Table 1) and that when activated concurrently, Stat1 and Stat3 engage in a heterodimer
formation. We deduce that overall, the binding of Stat3 (or
Stat3 SH2 domain) or SPI to the Stat1 pY701 peptide is weaker
compared with their binding to the pTyr peptides derived
from the IL-6R/gp130, pY705Stat3, or the pY1068EGFR. The
data together strongly suggest SPI and monomeric Stat3 have
preference for pStat3 monomer over pStat1 monomer. SPR
analysis similarly showed SPI, Stat3 SH2 domain, and Stat3
interact with the small-molecule, SH2 domain antagonist, S3I201, with KD values of 28.1, 21.5, 20.1 M, respectively (Fig. 2,
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S3I-201). Although weaker, the interactions with S3I-201
exhibit similar characteristics for SPI and Stat3 (or Stat3 SH2
domain). By contrast, data show that SPI, Stat3 SH2 domain,
and Stat3 interact poorly with the pTyr peptide of Stat5,
GpYVKPQ, with KD values of 7.3, 5.2, and 1.2 mM, respectively
(Fig. 2, GpYVKPQ), which indicate far weaker affinities for
Stat5, and which also suggest SPI, like Stat3, is more likely to
interact with pStat3 than pStat5. Furthermore, the data indicate
that interactions with pStat5 are rather a low probability, given
the millimolar affinities.
The studies so far demonstrate that SPI interacts with cognate pTyr peptide motifs recognized by Stat3 (or Stat3 SH2
domain). The interaction with SPI could block the binding of
Stat3 to its cognate pTyr peptide motifs. Fluorescence polarization (FP) study has previously been used to demonstrate the
binding of Stat3 (or Stat3 SH2 domain) to the high-affinity peptide, GpYLPQTV-NH2 (19, 20, 27). This assay was therefore
used to verify SPI binding to the high-affinity pTyr peptide
motif and to further assess the potential that such a binding
could disrupt the association of Stat3 with the same peptide
probe. Results of the FP assay, utilizing the 5-carboxyfluorescein-GpYLPQTV-NH2 as a probe, showed a similar binding
saturation profile, measured as fluorescence polarization signal
(mP), with the increasing concentration (in M) of purified HisStat3 (Fig. 3A, panel i) or SPI (Fig. 3A, panel ii), suggesting SPI
binds similarly as Stat3 to the pTyr peptide probe. Thus, SPI
behaves similarly to Stat3 in binding to cognate peptides. The
results show that the binding of the fluorescent probe to Stat3
causes a much higher polarization compared with binding to
SPI. This difference in the degree of polarization is not suggestive of differences in the affinities for the 5-carboxyfluoresceinGpYLPQTV-NH2 probe. Rather, it can be explained on the
basis of the little ability of larger molecules to tumble, and
hence, Stat3 protein being very large in size and much bigger
than SPI induces a higher degree of polarization. Compared
with Stat3, it would be expected that the SPI-bound probe
remains sufficiently small to facilitate some degree of tumbling
and therefore produces lower polarization. To further evaluate
the SPI:peptide probe interaction, relative to the binding of
Stat3 to the same probe, we compared the responsiveness of the
interactions to the known Stat3 dimerization inhibitor, S3I-201
(16). Here, fixed concentrations of each of Stat3 (200 nM) and
SPI (150 M) were incubated with increasing concentrations of
S3I-201 prior to incubation with the 5-carboxyfluoresceinGpYLPQTV-NH2 probe and subjected to FP measurements.
Consistent with the observed similarities in the saturation
curves (Fig. 3A), the profiles of the S3I-201-induced inhibition
of the binding to the labeled peptide probe are similar, regardless of whether Stat3 or SPI is the ligand (Fig. 3B, panel i, Stat3,
and B, panel ii, SPI). Next, we examined the potential that by
binding to the labeled pTyr peptide probe, SPI could compete
against Stat3. To address this, aliquots of fixed concentration of
Stat3 (0.8 M) were each incubated with a different concentration of SPI, prior to incubation with the fluorescein-labeled
probe and subjected to FP measurements. Results show a concentration-dependent decrease in FP signal when SPI is present
up to a certain concentration, when no further decreases
become evident (Fig. 3C), suggesting that SPI disrupts the interVOLUME 285 • NUMBER 46 • NOVEMBER 12, 2010
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FIGURE 2. SPR analysis. SPR analysis of the binding of SPI (A), Stat3 SH2 domain (B), or full-length Stat3 (C) to GpYLTQTV-NH2 (high affinity IL-6R/gp-130
peptide), PpYLKTK (Stat3 pTyr peptide), GpYIKTE (Stat1 pTyr peptide), GpYVKPQ (Stat5 pTyr peptide), PEpYINQS (EGFR pTyr peptide), PVpYHNQP (EGFR pTyr
peptide), and S3I-201 (Stat3 dimerization inhibitor). Data are representative of three independent determinations.

action of Stat3 with the cognate pTyr peptide probe. In this
context, the FP signal decreased to the levels consistent with the
displacement of Stat3 and the binding of SPI, as a ligand. The
lack of complete decay of the FP signal by SPI is due to the
observation in Fig. 3A, panel ii that SPI by itself behaves as a
NOVEMBER 12, 2010 • VOLUME 285 • NUMBER 46

ligand in binding to the fluorescent peptide probe and induces
polarization, although the FP signal is weaker than the signal
induced by Stat3 binding to the same probe, as previously surmised. These findings together demonstrate that SPI, like Stat3,
binds to cognate pTyr peptide motifs. By this mechanism, SPI
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 3. FP assay. FP assay of the binding to the 5-carboxyfluoresceinGpYLPQTV-NH2 probe of (A) increasing concentration of (i) purified His-Stat3
or (ii) SPI; (B) a fixed amount of (i) purified His-Stat3 (200 nM) or (ii) SPI (150 M)
in the presence of increasing concentrations of S3I-201; or (C) fixed amount of
Stat3 (0.8 M) in the presence of increasing concentrations of SPI. Data are
representative of four independent determinations.

would disrupt Stat3:Stat3 dimerization and the Stat3 binding to
cognate pTyr peptide motifs. The FP assay based on the 5-carboxyfluorescein-GpYLPQTV-NH2 probe and SPI was rigorously tested and validated, with a Z factor of 0.89.
Evidence of Intracellular Accumulation of SPI and Inhibition
of Intracellular Stat3 Activation—Stat3 is constitutively activated in a variety of malignant cells, including human breast
and pancreatic cancer cells (3–5). Given the effect against the
binding of Stat3 (or Stat3 SH2 domain) to cognate pTyr peptide
motifs, we asked the question whether SPI could inhibit Stat3
activation in malignant cells. To address this, we first evaluated
the extent of intracellular uptake of SPI by creating a 5-carboxyfluorescein-labeled version in which the fluorescence tag is
attached to the N terminus of SPI. In contrast to cells treated
with non-fluorescent SPI (negative control) (Fig. 4A, left two
panels), fluorescent microscopy analysis showed strong evidence of intracellular fluorescence (Fig. 4A and data not
shown), indicating significant cellular uptake of SPI following
treatment of cells, including the human breast cancer line,
MDA-MB-231 and the NIH3T3/hEGFR, with 30 M SPI.
Observation under higher magnification (40⫻) showed a wide
intracellular distribution of SPI, with nuclear accumulation (Fig.
4A, right panel), demonstrating SPI is membrane-permeable and
can localize in the nucleus. The mechanisms of cellular uptake and
nuclear translocation remain to be determined. Dose-response
studies reveal increasing intracellular uptake with increasing dose,
while time course studies suggest fluorescent signal is decreased,
but still evident by 22 h (supplemental Fig. S1). Malignant cells
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were then treated with SPI to assess biochemical and biological
effects. Treatment of v-Src-transformed mouse fibroblasts harboring aberrant Stat3 activity (NIH3T3/v-Src/pLucTKS3) (13,
14) and that stably over-express the Stat3-dependent luciferase
reporter, pLucTKS3 (13, 14, 29, 30) showed a dose-dependent
inhibition of Stat3-mediated luciferase reporter induction (Fig.
4, B(i)), demonstrating that SPI inhibits Stat3 transcriptional
activity. By contrast, a similar treatment of the v-Src-transformed mouse fibroblasts (NIH3T3/v-Src/pLucSRE) (13, 14)
that stably over-express the Stat3-independent luciferase
reporter, pLucSRE (29, 30), which is driven by the serum
response element (SRE) of the c-fos promoter, or of EGF-stimulated mouse fibroblasts transiently-transfected with the Stat5dependent ␤-casein-promoter-driven luciferase (␤-caseinLuc) (16) had minimal to no effect on the induction of these
reporters (Fig. 4B, panels ii and iii).
Consistent with the inhibition of Stat3 transcriptional activity, v-Src-transformed mouse fibroblasts (NIH3T3/v-Src), or
the human breast (MDA-MB-231 and MDA-MB-435), prostate (DU145), or pancreatic (Colo-357) cancer cells treated with
SPI showed a dose-dependent inhibition of constitutive Stat3
activation, as measured by DNA binding activity in nuclear
extract preparations using EMSA, with a near complete inhibition at 50 M (Fig. 4C, panel i). The induction of the EGF receptor in fibroblasts activates Stat1, Stat3, and Stat5, which form
homo- and hetero-dimers, as measured by DNA binding/
EMSA analysis (Fig. 4C, panel ii). Consistent with the effects on
Stat3 activation, the prior treatment of mouse fibroblasts overexpressing the human EGFR (NIH3T3/hEGFR) with 50 M SPI
completely blocked EGF-induced Stat3 activation, measured as
Stat3:Stat3:DNA complex (Fig. 4C, panel ii, left panel, upper
band), and suppressed the Stat1:Stat3 heterocomplex, measured
as Stat1:Stat3:DNA complex (Fig. 4C, panel ii, left panel, intermediate band). By contrast, similar treatment had little or no effect on
Stat1:Stat1:DNA complex (Fig. 4C, panel ii, left panel, lower band)
or Stat5:Stat5:DNA complex (Fig. 4C, panel ii, right panel).
Furthermore, immunoblotting analysis of whole cell lysates
prepared from SPI-treated NIH3T3/v-Src and MDA-MB231 cells showed a selective suppression of pY705Stat3 (Fig.
4D, panel i, upper panel), with no repression of pErk1/2 levels (Fig. 4D, panel i, lower panel). Total Stat3 protein levels
remain unchanged (Fig. 4D, panel i, upper panel). Immunoblotting analysis further shows no significant changes in the
general pTyr profile of v-Src-transformed mouse fibroblasts
treated with SPI (Fig. 4D, panel ii). Thus, at concentrations up to
50 M, SPI selectively and strongly inhibits constitutive Stat3 activation and transcriptional activity in malignant cells.
Biochemical Mechanism of Inhibition of Intracellular Stat3
Activation—We next examined the mode of inhibition of Stat3
activation. Per the SPR and FP studies, SPI will bind to pTyr
peptide motifs, thereby disrupt Stat3:Stat3 dimerization, as
observed for small molecule or peptidomimetic dimerization
disruptors of Stat3 (13, 14). Per the SPR data showing that both
Stat3 (or Stat3 SH2 domain) and SPI bind to the known Stat3
binding pY1068EGFR and pY1086EGFR motifs with comparable affinities, presumably, SPI, like the Stat3 SH2 domain will
associate with receptor pTyr motifs (Fig. 2). The binding to
receptor motifs will in turn obstruct Stat3 binding and thereby
VOLUME 285 • NUMBER 46 • NOVEMBER 12, 2010
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FIGURE 4. Intracellular uptake and effect of SPI on Stat3 activation. A, phase-contrast and fluorescence imaging of MDA-MB-231 cells following treatment
with 30 M fluorescently labeled (right two panels) or unlabeled (left two panels) SPI for 3 h; Image was captured using Zeiss Axiovert 200 microscope; B, cytosolic
extracts of equal total protein were prepared from 24-h SPI-treated or untreated (i) NIH3T3/v-Src/pLucTKS3 fibroblasts that stably express the Stat3-dependent
luciferase reporter (pLucTKS3), (ii) NIH3T3/v-Src/pLucSRE that stably express the Stat3-independent luciferase reporter (pLucSRE), or (iii) NIH3T3/hEGFR
transiently transfected with ␤-casein promoter-driven luciferase report (␤-casein-Luc) and stimulated with EGF and analyzed for luciferase activity using a
luminometer; (C) nuclear extracts of equal total protein were prepared from (i) the designated malignant cells or (ii) EGF-stimulated NIH3T3/hEGFR treated for
24 h with or without SPI and subjected to in vitro DNA binding assay using the radiolabeled hSIE probe (i) and (ii, left panel) that binds Stat1 and Stat3 or MGFe
probe (ii, right panel) that binds Stat1 and Stat5 and analyzed by EMSA; and (D) SDS-PAGE and Western blotting analysis of whole cell lysates of equal total
protein prepared from SPI-treated or untreated NIH3T3/v-Src and MDA-MB-231 cells and probing for (i) pY705Stat3, Stat3, pErk1/2, and Erk1/2, or (ii)
general pY profile. Positions of STATs:DNA complexes or proteins in gel are labeled; control lanes (0) represent cytosolic or nuclear extracts, or whole cell
lysates prepared from 0.05% DMSO-treated cells. Data are representative of 3– 4 independent determinations or mean and S.D. of 3 independent
determinations. *, p ⬍ 0.05; **, p ⬍ 0.01, and ***, p ⬍ 0.005.

block de novo Stat3 phosphorylation and activation. To verify
this and to determine the intracellular localization and colocalizations of SPI and EGFR, fluorescence microscopy, and immunofluorescence staining with laser-scanning confocal microscopy analyses were conducted. Cells were treated with the
fluorescently labeled SPI and subjected to immunostaining for
EGFR (red), as described under “Experimental Procedures.”
Results from the microscopy study showed that in MDA-MB231 cells treated with fluorescently labeled SPI (green), the
28-mer is widely distributed throughout cells, with a strong
nuclear localization (Fig. 5A, SPI, and merged, blue (DAPI), and
green (SPI)). Moreover, SPI and EGFR are colocalized at the
plasma membrane in MDA-MB-231 and in mouse fibroblasts
overexpressing EGFR (NIH3T3/hEGFR) and treated with fluorescently labeled SPI (Fig. 5, A and B, panel i, merged, yellow).
Moreover, to verify that SPI associates with Stat3, NIH3T3/
hEGFR cells were treated with the fluorescently labeled SPI
(green) and subjected to immunostaining for Stat3 (red), as
described under “Experimental Procedures.” Laser-scanning
NOVEMBER 12, 2010 • VOLUME 285 • NUMBER 46

confocal microscopy data showed that in unstimulated cells,
Stat3 and SPI are predominantly at the plasma membrane, with
weak presence in the cytoplasm and the nucleus, and with
little evidence of co-localization (Fig. 5B, panel ii, upper
panel), given that Stat3 is not phosphorylated. By contrast,
upon cell stimulation by EGF, the fluorescently labeled SPI
(green) and Stat3 (red) are universally distributed in the
cells, with a strong localization at the perinuclear region and
in the nucleus (Fig. 5B, panel ii, lower panel, green, red, and
blue (DAPI)), with evidence of colocalization (Fig. 5B, panel
ii, merged, green, red, and blue).
The observed colocalization indicates SPI associates with
EGFR. To test the assertion that SPI association with receptors
would compete against the binding of Stat3, thereby blocking
de novo activation, MDA-MB-231 cells were treated with or
without SPI for 12 h prior to treatment with sodium orthovanadate (protein phosphatase inhibitor) for an additional 12 h.
Analysis by in vitro DNA binding activity assay/EMSA of
nuclear extract preparations showed, as expected that the treatJOURNAL OF BIOLOGICAL CHEMISTRY
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in culture were treated with or
without an increasing concentration of SPI for 24 h and visualized
under phase-contrast microscope
for morphology changes, or analyzed for viable cell numbers by
CyQuant cell proliferation/viability
kit or by trypan blue exclusion with
phase-contrast microscopy. Compared with the control (DMSO
treatment), the human tumor cells
harboring aberrant Stat3 activity
(MDA-MB-231, MDA-MB-435,
DU145, Colo-357, and A549) and
treated with SPI showed significant
morphology changes and had reduced viable cell numbers (Fig. 6, A
and B, and data not shown). Importantly, the Stat3-dependent tumor
cell lines showed dose-dependent
decreases in viability and growth
following 24-h treatment with
FIGURE 5. Studies of colocalization of SPI with EGF receptor or Stat3 and the effect on Stat3 activa- increasing concentration of SPI
tion. A, fluorescence imaging of MDA-MB-231 cells treated with fluorescently labeled SPI (green; 30 M,
3 h), fixed, and stained with rabbit anti-EGFR antibody (red) or DAPI nuclear staining (blue), or (B) immu- (Fig. 6B, and data not shown). By
nofluorescence with laser-scanning confocal microscopy of unstimulated (⫺EGF) or EGF-stimulated contrast, the morphology, viability,
(⫹EGF, 10 ng/ml, 10 min) NIH3T3/hEGFR fibroblasts growing in culture and pretreated with fluorescently
and growth of cells that do not harlabeled SPI (green; 30 M, 3 h), fixed and stained with (i) rabbit anti-EGFR antibody (red) or (ii) rabbit
anti-Stat3 antibody (red), or DAPI nuclear staining (blue). Images were captured using Zeiss Axiovert 200 bor aberrant Stat3 activity (normal
fluorescent microscope or Leica TCS SP5 laser-scanning confocal microscope; or (C) Nuclear extracts were NIH3T3, human breast cancer,
prepared from MDA-MB-231 cells pretreated with or without SPI prior to treatment with or without
sodium orthovanadate and subjected to in vitro DNA binding assay using the radiolabeled hSIE probe and MCF-7, murine thymus stromal
analyzed by EMSA. Positions of STATs:DNA complexes in gel are labeled; control (⫺), no treatment. Data epithelial cells, TE-71 and prostate
are representative of three independent studies.
cancer, LNCaP) were not significantly affected by similar treatment
ment with SPI alone inhibits Stat3 DNA binding activity (Fig. with SPI (Fig. 6, A and B, and data not shown). Furthermore,
5C, lane 2, compared with lane 1), while the treatment with cultured MDA-MB-231 cells that harbor aberrant Stat3 activity
orthovanadate alone increased Stat3 activity above the existing and treated with SPI for 24 h and subjected to Annexin V bindlevels (Fig. 5C, lane 3, compared with lane 1), the latter, which is ing/flow cytometry analysis showed evidence of significant
in part due to the blockade of the pStat3 turnover by the inhi- apoptosis (35%), compared with DMSO-treated control (6%),
bition of protein phosphatases. By contrast, unlike cells treated while the normal NIH3T3 fibroblasts similarly treated showed
with orthovanadate alone, in cells treated first with SPI and little evidence of apoptosis, compared with DMSO-treated
then with orthovanadate, Stat3 activation was completely control (Fig. 6C, left panel). These data together indicate that
inhibited (Fig. 5C, lane 4). This can be explained on the basis of SPI selectively represses constitutive Stat3 activation in maligthe blockade of de novo Stat3 activation (by SPI), concomitant nant cells, thereby inducing antitumor cell effects that are
with the physiological turnover (elimination) of pre-existing dependent on the presence of constitutively active Stat3 in cells.
pStat3 during the period prior to the addition of orthovanadate.
Thus, by the time of the orthovanadate addition, there were no DISCUSSION
residual pStat3 levels. The microscopy and the gel shift data
Protein-protein interactions are a common molecular event
together demonstrate that SPI associates with Stat3 binding important in signal transduction and many other physiological
motifs of receptors, consequently preventing de novo Stat3 processes. In the case of Stat3, the recruitment via the SH2
phosphorylation.
domain to cognate receptor pTyr peptide motifs is a key initial
SPI Blocks Cell Viability and Growth, and Induces Apoptosis step for phosphorylation. Data herein show that the Stat3 SH2
of Malignant Cells Harboring Constitutively Active Stat3—Ab- domain-derived 28-mer peptide, SPI alone is sufficient to
errantly active Stat3 promotes malignant cell proliferation and reproduce some aspects of the biochemical properties of Stat3
survival and malignant transformation (4, 5, 39). We asked the (or the Stat3 SH2 domain), thereby serving as a critical motif
question whether SPI is able to selectively decrease the viability that engages in the inter-molecular interactions with the key
and growth of malignant cells that harbor aberrant Stat3 activ- residues of the cognate pTyr peptides to which Stat3 binds.
ity. The human breast (MDA-MB-231 and MDA-MB-435), Using biophysical analysis, such as SPR, we demonstrate simipancreatic (Colo-357), prostate (DU145), and non-small cell larities in the binding characteristics of Stat3 (or Stat3 SH2
lung cancer (A549) lines that harbor constitutively-active Stat3 domain) and SPI to known cognate pTyr peptides, including
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ther evident by the SPR analysis that
further suggests rather unfavorable
interactions with the native Stat5
phosphopeptide, pY694Stat5, with
affinities that are in milli-molar
concentrations (KD of 1–7 mM).
Together, present studies indicate
SPI, like Stat3, shows preferential
binding to different cognate pTyr
peptide motifs, specifically showing
stronger binding to the Stat3 phosphopeptide, compared with weaker
binding to the Stat1 phosphopeptide. Given the observed differences
in the affinities, we surmise that the
type and number of binding partners to which Stat3 (or Stat3 SH2
domain) or SPI would interact with
would be strongly influenced by
their intracellular concentrations.
Fluorescence polarization analysis
based on the binding to the gp130derived peptide (as 5-carboxyfluorescein-GpYLPQTV-NH2), (40),
further support the similarities in
the binding characteristics between
SPI and Stat3.
The ability to mimic the SH2
domain and interact with pTyr peptide motifs raises the possibility that
SPI could compete against Stat3.
This assertion is supported by the
fluorescence polarization studies
that SPI strongly competes against
Stat3 for the binding to IL-6R/gp13derived pTyr peptide probe. Furthermore, evidence is presented
that SPI exhibits selectivity at certain concentrations in the inhibition
of intracellular Stat3 phosphorylation, DNA-binding and transcriptional activities. The inhibition of
intracellular Stat3 activation may be
explained in part by the ability to
FIGURE 6. SPI induces morphology change, suppresses viability, and induces apoptosis of malignant disrupt Stat3:Stat3 dimerization, as
cells that harbor persistently active Stat3. A, photomicrographs of human breast (MDA-MB-231, MDA-MB- has been observed for other Stat3
435, and MCF-7), prostate (DU145 and LNCaP), non-small cell lung (A549), and pancreatic (Colo-357) cancer dimerization inhibitors (13, 14, 16,
cells, murine thymus stromal epithelial (TE-71) cells, and normal mouse fibroblasts (NIH3T3) in culture were
treated once or untreated with 50 M SPI for 24 h; (B) indicated cells were untreated or treated once with 17), and on the basis of the potential
increasing concentration of SPI for 24 h and assayed for viability using CyQuant cell proliferation kit; or (C) that by associating with receptor
human breast cancer cells (MDA-MB-231) or normal mouse fibroblasts (NIH3T3) in culture were untreated
pTyr motifs, SPI could block Stat3(control) or treated once with SPI (40 M, 24 h) and subjected to Annexin V and 7-AAD binding and analyzed by
binding to receptors, and hence preflow cytometry for apoptosis. Data are representative of 3– 4 independent determinations.
vented de novo phosphorylation.
the native IL-6R/gp-130 derived peptide, GpYLPQTV-NH2, Thus, while the treatment of cells with the protein phosphatase
the Stat3 peptide, pY705Stat3, and the EGFR motif, inhibitor, sodium orthovanadate alone, increased the levels of
pY1068EGFR, which Stat3 and SPI interact relatively stronger, activated Stat3 above constitutive levels, due to the blockade of
and to the EGFR motif, pY1086EGFR and the Stat1 peptide, pStat3 turnover by protein phosphatases, the prior exposure
pY701Stat1, which they bind to with rather low affinities. The of cells to SPI squelched any subsequent orthovanadate-induced
similarity in the binding characteristics of SPI and Stat3 is fur- accumulation of activated Stat3. Moreover, the observation
NOVEMBER 12, 2010 • VOLUME 285 • NUMBER 46
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that SPI exhibits preferential inhibition of Stat3 activation relative to Stat1, despite the physiological occurrence of a Stat1:
Stat3 heterodimer, when the two STAT family members are
concurrently activated by EGF, suggests not only does SPI have
preference for Stat3 over Stat1, but also that activated Stat3
protein may prefer to form a homodimer when concurrently
activated with Stat1.
The SPI-mediated inhibition of Stat3 activation, via binding to cognate pTyr peptide motifs, is in direct converse to
the mechanisms of Stat3 inhibition by many of the existing
Stat3-inhibitory modalities, which are pY peptide mimetics
and bind to the Stat3 SH2 module (4, 5, 13–15, 19, 22, 40, 41),
or to the approaches that have been reported for the inhibition of other SH2 domain-containing proteins, such as the
adapter protein, Grb2 (12), although the biochemical outcome of the inhibition would be the same, which is to disrupt
pY:SH2 domain interactions. Whereas there are many protein entities with an SH2 module that are involved in promoting signal transduction and other biochemical processes
(8, 9), present findings provides evidence of specificity for
SPI action, which is demonstrated in the lack of effect on
EGF-induced Stat5 activation and transcriptional activity,
ErkMAPK activation, the c-fos-promoter-driven luciferase
reporter, or on Stat1 activation at concentrations that inhibit
Stat3 activity. Accordingly, antitumor cell effects of SPI are
observed at concentrations that inhibit Stat3 activity and are
consistent with the blockade of aberrant Stat3 activation (4,
5, 13–15, 40, 41). Specifically, human breast, pancreatic,
prostate, and non-small cell lung cancer cells harboring
aberrant Stat3 activity are more sensitive to SPI. We note an
increased nuclear accumulation of SPI in malignant cells,
which we speculate will promote a stronger degree of inhibition of nuclear activated Stat3 and Stat3 transcriptional
activity. By contrast, in mouse fibroblasts overexpressing the
EGFR in which Stat3 is not aberrantly-activated, SPI is predominantly localized to the cell membrane. The mechanism(s) for the cellular uptake and the nuclear translocation,
and whether there are specific factors that promote the
increased nuclear localization in malignant cells remain to
be determined. Herein is reported a Stat3 SH2 domain-mimetic
that functions as an inhibitor of Stat3 activation. The approach to
the inhibition of Stat3 activation by SPI avoids the known challenges of mimicking the pTyr functionality for the existing SH2
domain-binding inhibitors. The significant in vitro activity of SPI
makes it a suitable candidate for developing a modality for further
evaluation of in vivo effects. Furthermore, SPI serves as a valuable
molecular probe for interrogating aberrant Stat3 functions in
tumor processes and for designing in vitro pY peptide binding
assays.
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